BlackRock, Inc. 13D and 13G filings for Intra-Cellular Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Intra-Cellular Therapies, Inc. ITCI | BlackRock Inc. BLK | 6,218,671 5.900% | 0 (Unchanged) | Filing |
| 2024-10-24 2:02 pm Sale | 2024-09-30 | 13G | Intra-Cellular Therapies, Inc. ITCI | BlackRock Inc. BLK | 6,218,671 5.900% | -1,974,316 (-24.10%) | Filing |
| 2024-01-25 1:48 pm Purchase | 2023-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | BlackRock Inc. BLK | 8,192,987 8.500% | 743,458 (+9.98%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | BlackRock Inc. BLK | 7,449,529 7.900% | 1,727,763 (+30.20%) | Filing |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | BlackRock Inc. BLK | 5,721,766 7.000% | -176,802 (-3.00%) | Filing |
| 2021-01-29 09:57 am Purchase | 2020-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | BlackRock Inc. BLK | 5,898,568 7.400% | 1,988,057 (+50.84%) | Filing |
| 2020-02-05 11:46 am Sale | 2019-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | BlackRock Inc. BLK | 3,910,511 7.100% | -94,155 (-2.35%) | Filing |